Key facts
- This page summarizes Terrie Curran's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Mar 2025, 17:16.
Terrie Curran - 27 Feb 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)
- Reporting relationship
- President and Chief Executive, Director
- Issuer ticker
- PHAT
- Reported as of
- 27 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2025, 17:16:33 UTC
- Prior SEC filing
- 23 Jan 2025
- Next SEC filing
- 16 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Molly Henderson, Attorney-in-Fact for Terrie Curran
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Terrie Curran filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 03 Mar 2025.
Change
- Previous filing in this sequence was filed on 23 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHAT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +342,500
- Change %
- Price
- $0.000000
- Shares after
- 342,500
- Date
- 27 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 342,500
- Exercise price
- $5.76
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.